Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: Ipamorelin acetate
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Ghrelin-receptor agonist peptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Stimulates ghrelin-receptor pathways; selectivity does not mean risk-free GH enhancement.
Evidence and critical reading
Reported scientific and empirical uses
GH/IGF hormonal axis
Handbooks describe body composition, recovery and GHRH combinations. Postoperative-ileus evidence cannot be presented as proof of sports recovery.
Human evidence
Postoperative ileus randomized trial did not meet its key meal-tolerance endpoint; no validation of bodybuilding or recovery stacks.
Preclinical evidence
Receptor pharmacology does not demonstrate long-term functional gains.
Critical reading and limitations
A phase II trial enrolled 117 participants and found no significant difference in its primary solid-food-tolerance endpoint. Administration was intravenous in hospital, unlike community subcutaneous cycles. A lower response of another hormone does not establish general safety.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by 2.pdf
100; 300–500 mcg · Amount per administration
- Frequency
- 1–3 times daily; quantities presented by “level”.
- Duration
- 8–12 weeks per source.
- Route
- Subcutaneous
- Context
- Tiered handbook regimen, not an escalation recommended by this guide.
- Presentation
- Not stated on selected page.
- Interpretation
- Does not validate efficacy or safety of this regimen; attributed to the handbook.
manual07 · Page 18 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Serious events occurred in a postoperative IV setting; causality is not assumed. Other injectable routes have inadequate safety data.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID25331030 · Randomized placebo-controlled phase II
Post-bowel-surgery patients; 114 in safety analysis.
Hospital intravenous administration.
No significant difference in primary solid-food endpoint (p=0.15).
Population and route differ from community SC cycles.
n = 117
Trials attributed in the package
NCT00672074 · Safety and Efficacy of Ipamorelin for Management of Post-Operative IleusRegistry status: CompletedLast update posted: April 14, 2017Query verification: October 16, 2026
NCT01280344 · Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal FunctionRegistry status: CompletedLast update posted: April 13, 2017Query verification: October 16, 2026
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Ipamorelin · 3 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07717866 · Trifecta Research StudyRegistry status: Active, not recruitingLast update posted: July 21, 2026Query verification: October 16, 2026
NCT00672074 · Safety and Efficacy of Ipamorelin for Management of Post-Operative IleusRegistry status: CompletedLast update posted: April 14, 2017Query verification: October 16, 2026
NCT01280344 · Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal FunctionRegistry status: CompletedLast update posted: April 13, 2017Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID25331030
Beck DE, Sweeney WB, McCarter MD, Ipamorelin 201 Study Group.
October 16, 2026
- R06
- R12
- manual07
2.pdf
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026